Through the ASTRRA trial, we can determine optimal endocrine therapy based on real-time ovarian function status for each premenopausal breast cancer patient with estrogen receptor-positive disease who received neoadjuvant or adjuvant chemotherapy. The gene discussed is ESR1; the disease is glycogen storage disease VI.